The Cbl proteins are a family of proteins found in metazoans from nematodes to vertebrates. These proteins have several highly conserved domains including an N-terminal tyrosine kinase binding (TKB) 1 domain and a RING finger (1-9). The three mammalian Cbl proteins, 2, [6] [7] [8] , are tyrosine-phosphorylated upon activation of a wide variety of growth factor receptors, and they associate with many signaling proteins via SH2 and SH3 interactions (reviewed in Ref. 10 and 11). These diverse interactions modulate signaling through many pathways (10, 11) . Recent work has shown that c-Cbl-and Cblb-deficient mice have hyperplastic tissues, consistent with a negative regulatory role in cellular proliferation for Cbl proteins (12-15). Together, these data indicate that the Cbl proteins are important regulators of intracellular signaling and consequently of cell function and development.
The Cbl proteins are a family of proteins found in metazoans from nematodes to vertebrates. These proteins have several highly conserved domains including an N-terminal tyrosine kinase binding (TKB) 1 domain and a RING finger (1) (2) (3) (4) (5) (6) (7) (8) (9) . The three mammalian Cbl proteins, c-Cbl, Cbl-b, and Cbl-3 (1, 2, 6 -8) , are tyrosine-phosphorylated upon activation of a wide variety of growth factor receptors, and they associate with many signaling proteins via SH2 and SH3 interactions (reviewed in Ref. 10 and 11) . These diverse interactions modulate signaling through many pathways (10, 11) . Recent work has shown that c-Cbl-and Cblb-deficient mice have hyperplastic tissues, consistent with a negative regulatory role in cellular proliferation for Cbl proteins (12) (13) (14) (15) . Together, these data indicate that the Cbl proteins are important regulators of intracellular signaling and consequently of cell function and development.
Cbl proteins are negative regulators of epidermal growth factor receptor (EGFR) signaling. This was first shown by genetic studies in Caenorhabditis elegans, which demonstrated that Sli-1 (the C. elegans Cbl homologue) is a negative regulator of the Let-23 receptor tyrosine kinase (the EGFR homologue) in vulva development (3, 16) . The Drosophila Cbl protein (D-Cbl) has been shown to associate with the EGFR, and overexpression of D-Cbl in the eye of Drosophila embryos inhibits EGFR-dependent photoreceptor cell development (4, 5) . Several studies have shown that mammalian Cbl proteins become phosphorylated and recruited to the EGFR upon stimulation (11, 17) and that they inhibit EGFR function (7, 18 -20) .
The mechanism underlying the negative regulation of activated tyrosine kinases by Cbl proteins has recently been described. Cbl proteins function as ubiquitin protein ligases, which mediate the ubiquitination of activated tyrosine kinases including the EGFR and target them for degradation (20 -31) . Ubiquitination of proteins occurs via the sequential activation and conjugation of ubiquitin to target proteins by the ubiquitinactivating enzyme (E1), a ubiquitin-conjugating enzyme (E2), and a ubiquitin protein ligase (E3) (32) . The E3 confers specificity to the ubiquitination process. An increasing number of RING finger proteins has been demonstrated to function as E3 proteins or as part of E3 complexes, and in each of them the RING finger is essential to this activity (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) . The highly conserved TKB and RING finger domains of Cbl proteins are essential and sufficient for their E3 activity, and together these domains target the ubiquitination of activated tyrosine kinases such as the EGFR (20 -31) .
Here, we show that EGF activation induces a coordinated degradation of the EGFR, Cbl proteins, and other proteins of the EGFR signaling complex. These results suggest that Cbl proteins regulate degradation of multiple proteins in the active EGFR-signaling complex.
EXPERIMENTAL PROCEDURES
Expression Constructs-The expression plasmid for HA epitopetagged Cbl-b, c-Cbl, and the control vector (pCEFL) have been previously described (18) . HA epitope-tagged Cbl-b N1/3 (amino acids 1-349) and C2/3 (327-938) were created by polymerase chain reaction amplification and cloning into the pCEFL vector. The N-terminal half (N1/2) of Cbl-b (amino acids 1-483) was created by deleting the C-terminal of the full-length wild type Cbl-b in pCEFL, and in the process the HA epitope was lost. The GST fusion protein for Cbl-b N1/2 (amino acids 29 -483) was created by in-frame cloning of a polymerase chain reaction-generated N-terminal fragment of Cbl-b into pGEX 2TK (Amersham Pharmacia Biotech). The C373A was created in both the fulllength wild type Cbl-b in pCEFL and in the GST-Cbl-b N1/2 fusion protein by site-directed mutagenesis (QuikChange kit; Stratagene). All of the mutant Cbl-b constructs were confirmed by sequencing. The EGFR Y1045F mutant expression construct in pcDNA3 has been pre-* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
viously described (26) . The GFP expression plasmid (pcDNA3.1/zeo) was obtained from Invitrogen.
Immunoblotting and Immunoprecipitation-Immunoblotting and immunoprecipitation were performed as previously described (18) . Anti-Akt (New England Biolabs), anti-Cbl-b (H454; Santa Cruz Biotechnology), anti-EGFR (1005; Santa Cruz Biotechnology), anti-ERK-2 antibody (SC154; Santa Cruz Biotechnology), anti-Grb-2 (C-23; Santa Cruz Biotechnology), anti-HA (Y-11; Santa Cruz Biotechnology), horseradish peroxidase-conjugated anti-phosphotyrosine (4G10; Upstate Biotechnology), anti-p85 subunit of phosphatidylinositol 3-kinase (06 -195; Upstate Biotechnology), and anti-Shc (Transduction Laboratories, Inc.) were used for immunoblotting. Ubiquitination was assayed as previously described using a rabbit polyclonal anti-ubiquitin antibody (44) . Mouse monoclonal anti-EGFR antibody (Ab-3; Oncogene Science) and anti-phosphotyrosine (4G10; Upstate Biotechnology) were used for immunoprecipitation.
Cell Culture-MDA-MB-468 breast cancer cells were obtained from the ATCC and maintained in culture in RPMI 1640 supplemented with 10% fetal calf serum and 1% penicillin-streptomycin. Stable clones overexpressing wild type and mutant forms of Cbl-b were generated as previously described (20) . To measure the biochemical effects of EGF stimulation, MDA-MB-468 cells were grown to 50 -70% confluence, starved overnight in RPMI 1640 supplemented with 0.5% fetal calf serum, and then stimulated with EGF (100 ng/ml; Collaborative Biomedical Products) for the times indicated. To harvest proteins, the cells were washed two times in ice-cold phosphate-buffered saline containing 0.2 mM sodium orthovanadate, and the cells were lysed in ice-cold lysis buffer (10 mM Tris HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 10% glycerol, 100 mM iodoacetamide, 2 mM sodium orthovanadate, and protease inhibitors (Complete tabs®, Roche Molecular Biochemicals)). The lysates were cleared of debris by centrifugation at 16,000 ϫ g for 15 min at 4°C. In experiments to rule out sequestration of Cbl-b upon EGF stimulation, the cells were lysed in SDS buffer (2% SDS, 20 mM Tris HCl, pH 7.5, 50 mM NaCl, 5 M dithiothreitol), boiled for 5 min, sonicated, and then run on SDS-polyacrylamide gels without clarification of the lysates. To assess the biochemical effects in the presence of protease inhibitors (e.g. lactacystin, NH 4 Cl, or Z-VAD-fmk), cells were starved as above, the protease inhibitor was added 2 h before EGF, and lysates were prepared as above. To induce apoptosis in the MDA-MB-468 breast cancer cells, cells were incubated with the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and doxorubicin as previously described (45) .
293T cells were maintained in culture in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and 1% penicillinstreptomycin and transfected with various constructs using calcium phosphate (5 Prime 3 3 Prime, Inc., Boulder, CO) according to the protocol included with the reagents. To measure the effects of EGF stimulation, 293T cells were grown to 70% confluence, starved overnight in Dulbecco's modified Eagle's medium supplemented with 0.5% fetal calf serum, and then stimulated with EGF (100 ng/ml) for the times indicated. Proteins were harvested as describe above for MDA-MB-468 cells.
In Vitro Ubiquitination Assay-Autoubiquitination of Cbl proteins was performed as previously described (40) . Briefly, GST or GST fusion proteins were incubated in the presence or absence of recombinant wheat E2 (20 ng; UbcH5B) along with recombinant wheat E1 (20 ng) and 32 P-Labeled ubiquitin (2 ϫ 10 4 cpm), in ubiquitination buffer (50 mM Tris-HCl, pH 7.4, 2 mM adenosine 5Ј-triphosphate, 5 mM MgCl 2 , and 2 mM dithiothreitol) at 30°C for 90 min. The reaction mixture was separated by 7.5% SDS-polyacrylamide gel electrophoresis and visualized with a Storm PhosphorImager and Image Quant software (Molecular Dynamics). After exposure, the gels were stained with Coomassie Blue to ensure that similar amounts of GST fusion proteins had been used.
RESULTS

Cbl-b Is Down-regulated upon EGF Stimulation-
In prior work, we demonstrated that overexpressing Cbl-b in the MDA-MB-468 breast cancer cell line enhances EGF-induced ubiquitination and degradation of the EGFR (20) . This results in inhibition of EGFR function. During further investigations of activation-induced down-regulation of the EGFR by Cbl-b in these MDA-MB-468 cells, we observed that there was an activation-induced loss of Cbl-b that parallels the decrease in the EGFR (Fig. 1A, lanes 1-7) . In the absence of Cbl-b, the EGFR showed only minimal degradation (Fig. 1A, lanes 8 -14) . Cbl-b degradation did not reflect a general decrease of cellular proteins, as Akt and ERK-2 protein levels did not change. These results were confirmed in multiple independent Cbl-b and vector clones. This change in protein level was not due to changes in mRNA, as the level of exogenous Cbl-b mRNA, measured by Northern analysis, was stable throughout the time course of the experiment (Fig. 1B) . To demonstrate that the observed decrease in Cbl-b protein represented a loss of protein and not sequestration in an insoluble compartment, cell lysates were prepared from EGF-starved and stimulated cells by resuspending the cells in a 2% SDS lysing buffer, boiling, and then sonicating the lysates. The lysates were run on SDS-polyacrylamide gels without clarification. In these lysates, Cbl-b protein levels still were observed to decrease upon EGF stimulation (Fig. 1C) .
Clones of the MDA-MBA-468 cell line, which expressed higher levels of Cbl-b, demonstrated progressively less EGFinduced down-regulation of Cbl-b ( Fig. 2A ). This suggested that the mechanism of EGF-induced down-regulation of Cbl-b is saturable. When high levels of Cbl-b are expressed (as in clone B.29), EGF induces down-regulation of only a small fraction of the total Cbl-b. Thus, changes in the Cbl-b protein level are not appreciated in the highest expressors. In contrast, all of the Cbl-b clones down-regulated the EGFR to an equal degree as the clone shown in Fig. 1 (data not shown). This indicates that even the lowest expressing clone has sufficient Cbl-b to effectively target the EGFR for degradation. These observations further suggest that there might be a stoichiometric relationship between the levels of Cbl-b, the EGFR, and the downregulation of both proteins.
To test whether levels of each protein (EGFR and Cbl-b) affected the degradation of the other, a constant amount of the EGFR was co-expressed in 293T cells with varying amounts of Cbl-b (Fig. 2B) . When 3.0 g of Cbl-b plasmid was transfected along with 1.0 g of the EGFR plasmid, no EGF-induced decrease in Cbl-b was observed despite down-regulation of the EGFR (Fig. 2B, lanes 1 and 2) . In contrast, when 0.3 g of Cbl-b plasmid was transfected along with 1.0 g of the EGFR plasmid, EGF induced a decrease in the Cbl-b protein but no decrease in the EGFR (Fig. 2B, lanes 3 and 4) . When the expression of both proteins is titrated optimally, EGF-induced down-regulation of both proteins was observed ( Fig. 2C; lane 4) . In addition, to determine whether EGF induced a similar down-regulation of c-Cbl, c-Cbl and EGFR were transiently co-expressed in 293T cells. Activation-induced down-regulation of c-Cbl and the EGFR was observed ( To test if EGF induced degradation of endogenous Cbl proteins, MDA-MB-468 cells were stimulated with EGF, lysates were prepared, and protein levels were assessed by immunoblotting (Fig. 2D) . EGF induced degradation of the endogenous c-Cbl and Cbl-b (Fig. 2D, lane 2) . In these cells there was only slight degradation of the EGFR. This result is concordant with the titration data described above (Fig. 2, A-C) , since these cells have high levels of the EGFR and relatively low levels of endogenous Cbl proteins. These results confirmed that EGF induces degradation of endogenous Cbl proteins and further confirmed the stoichiometric relationship described above.
Cbl-b Is Ubiquitinated and Degraded in a Proteasome-dependent Fashion-Degradation of activated EGFRs is sensitive to both proteasome and lysosome inhibitors (22, 46, 47) . Thus, EGFR degradation is dependent on both the proteasomal and lysosomal pathways. To test if Cbl-b degradation occurred by a mechanism similar to that of EGFR degradation, MDA-MB-468 cells overexpressing Cbl-b were stimulated with EGF in the presence or absence of lactacystin (an inhibitor of proteasomes (48)). Lactacystin inhibited EGF-induced degradation of both Cbl-b and the EGFR proteins but had little or no effect on the level of the proteins in the absence of EGF simulation ( Fig. 3A ; top panels). Similar inhibition of EGF-induced degradation was seen when cells were incubated with inhibitors of lysosome function (e.g. ammonium chloride (47)) (data not shown). In contrast, the caspase inhibitor Z-VAD-fmk did not block EGFinduced degradation of Cbl-b or the EGFR ( Fig. 3A; bottom panels). Cbl proteins have been shown to be degraded during apoptosis (49) . We have previously demonstrated that the combination of TRAIL and doxorubicin induce apoptosis in MDA-MB-468 cells, and this can be blocked by caspase inhibitors (45) . Z-VAD-fmk inhibited the degradation of Cbl-b and poly-(ADP-ribose) polymerase, which occurs during apoptosis (Fig.  3B) . These inhibitor experiments suggest that EGF induces a common degradation pathway for both Cbl-b and the EGFR involving both the proteasome and the lysosome. Furthermore, they demonstrate that the degradation of Cbl-b induced by EGF occurs via a distinct mechanism from the degradation seen during apoptosis.
The EGFR is targeted for degradation by activation-induced ubiquitination mediated by the Cbl proteins (20, 22, 23, (25) (26) (27) . To test if Cbl-b is also ubiquitinated, Cbl-b was immunoprecipitated from cell lysates starved or stimulated with EGF in the presence of lactacystin and then immunoblotted with a
FIG. 2. EGF-induced degradation of Cbl-b and EGFR requires the presence of both proteins.
A, clones of the MDA-MB-468 cell line expressing different amounts of Cbl-b were starved (Ϫ) or stimulated (ϩ) with EGF (100 ng/ml) for 6 h, and lysates were immunoblotted for Cbl-b. Loading levels were confirmed to be equal by reprobing the blots with ERK-2 (not shown). B, 293T cells were transfected with a fixed amount of EGFR plasmid and varying amounts of Cbl-b plasmid, as indicated above the panels. Cells were starved or stimulated with EGF for 6 h, and lysates were immunoblotted (IB) for Cbl-b (HA), EGFR, and GFP as indicated to the right of the panels. C, 293T cells were transfected with EGFR plasmid (0.5 g) and either Cbl-b, c-Cbl, or empty vector plasmids (0.3 g), as indicated above the panels. Cells were starved (-) or stimulated (ϩ) with EGF for 6 h, and lysates were immunoblotted for Cbl-b or c-Cbl (HA), EGFR, and GFP as indicated to the right of the panels. GFP was included in the 293T transfections as a control for protein loading and transfection efficiency. D, a vector clone of the MDA-MB-468 cell line was starved (Ϫ) or stimulated (ϩ) with EGF (100 ng/ml) for 6 h, and lysates were immunoblotted for endogenous Cbl-b, c-Cbl, EGFR, or ERK-2.
polyclonal anti-ubiquitin antibody (Fig. 4) . In cells overexpressing Cbl-b, EGF activation results in the appearance of a smear of anti-ubiquitin immunoreactive species in the Cbl-b immunoprecipitates, indicative of the addition of multiple ubiquitin molecules to Cbl-b (Fig. 4; lane 4) . Similarly, EGF induced ubiquitination of the EGFR (Fig. 4, lane 8) . Notably, the ubiquitinated forms of Cbl-b begin at a smaller size (ϳ125 kDa) than the un-ubiquitinated EGFR (ϳ180 kDa), indicating that the higher molecular mass ubiquitinated proteins are not coprecipitating ubiquitinated EGFRs. Similarly, the ubiquitinated species detected in the EGFR immunoprecipitates migrate above the position of the un-ubiquitinated EGFR (Fig. 4,  lane 8) . Thus, Cbl-b becomes ubiquitinated upon EGF activation.
Structural Requirements for Cbl-b Degradation-The ability of Cbl proteins to induce ubiquitination and degradation of activated EGFRs requires an intact TKB and RING finger domain (23, (25) (26) (27) . To assess the structural requirements for Cbl-b ubiquitination and degradation, stable clones of the MDA-MB-468 cell line expressing mutant forms of Cbl-b were generated. EGF activation of cells expressing full-length Cbl-b or the Cbl-b N1/2 (which contains both the TKB and RING finger domains) resulted in down-regulation of both the Cbl-b and EGFR proteins (Fig. 5A) . Both of these forms of Cbl-b are recruited to the EGFR upon activation. These results also demonstrate that proline-rich SH3 docking sites and the ubiquitin-associated domain in the C-terminal half of Cbl-b are not required for Cbl-b or EGFR down-regulation. In contrast, EGF activation of cells expressing mutants of Cbl-b that have deletions of either the RING finger or the TKB domain (N1/3 and C2/3, respectively) does not result in down-regulation of either the Cbl or EGFR proteins. The N1/3 protein (containing the TKB domain) coimmunoprecipitated with the activated EGFR, whereas the C2/3 protein (lacking the TKB domain) did not. Thus the TKB and RING finger domains are required for downregulation of both Cbl-b and the EGFR.
Titration experiments in 293T cells with the Cbl-b N1/2 protein demonstrated similar results to those seen with fulllength Cbl proteins (Fig. 5B) . When protein levels of Cbl-b N1/2 are high and EGFR levels are low, EGF-induced degradation of the EGFR is seen, but no degradation of Cbl-b N1/2 is appreciated (Fig. 5B, lanes1 and 2) . When protein levels of the EGFR are high and Cbl-b N1/2 levels are low, EGF induced degradation of Cbl-b N1/2 is observed, but no degradation of the EGFR is seen (Fig. 5B, lanes 5 and 6) . Optimal titration of the protein levels results in EGF-induced degradation of both proteins (Fig. 5B, lanes 3 and 4) . These results again suggest a stoichiometric relationship between the EGF-induced degradation of Cbl-b and the EGFR.
To directly assess the role of the RING finger in activationinduced Cbl-b down-regulation, a point mutation was introduced in the first cysteine of the Cbl-b RING finger (C373A). This point mutation resulted in the complete abrogation of EGF-induced down-regulation of both the EGFR and the mutant Cbl-b and an accompanying loss of ubiquitinated forms of both proteins (Fig. 5A and data not shown) . To confirm that this mutation destroyed the ability of Cbl-b to function as an E3, bacterially produced GST fusion proteins for Cbl-b (N1/2) with or without the C373A mutation were tested in an in vitro ubiquitination reaction in which the fusion protein serves as the primary substrate (40) . As is evident, Cbl-b mediates its own ubiquitination, whereas the C373A mutant does not (Fig.  5C ). These data establish that the EGF-induced ubiquitination and down-regulation of Cbl-b has the same structural requirements as those needed for EGFR ubiquitination and downregulation. Down-regulation of both proteins requires intact Cbl-b TKB and RING finger domains.
Cbl-b Down-regulation Requires Binding to the EGFR-Previous work has shown that EGFR down-regulation by Cbl proteins requires binding of the Cbl protein to the activated receptor (22, 23, 26, 27) . The apparent stoichiometric relationship between Cbl-b degradation and EGFR degradation (described in Figs. 2 and 5B) and the structural requirements for both an intact TKB domain and RING finger (described in Fig.  5 ) suggested that EGF-induced down-regulation of the Cbl-b protein requires binding of Cbl-b to the EGFR. To directly test this, we transiently co-expressed Cbl-b with either wild type EGFR or a mutant EGFR (Y1045F-EGFR) to which Cbl proteins cannot bind (Fig. 6A) . Previous work has shown that the Y1045F-EGFR has a catalytically active kinase but that Cbl proteins do not induce its ubiquitination or down-regulation (26) . Down-regulation of Cbl-b and EGFR was observed only when Cbl-b was co-expressed with the wild type EGFR. No down-regulation of either protein was observed when Cbl-b was co-expressed with the Y1045F-EGFR. These lysates were used to assess binding of Cbl-b to the wild type and mutant EGFR. As previously described (26) , Cbl-b coimmunoprecipitated with the EGF-stimulated wild type EGFR but not with the EGFstimulated Y1045-EGFR (Fig. 6B) . Cbl proteins become phosphorylated upon activation of the EGFR, and this is believed to be mediated indirectly by Src kinases that are activated upon stimulation of the receptor (17) . Immunoprecipitation of Cbl-b demonstrated that Cbl-b became phosphorylated in response to activation of either form of the receptor (demonstrating kinase activity for both forms of the EGFR) but also demonstrated that only the wild type form of the activated EGFR co-immunoprecipitated with Cbl-b (Fig. 6C) . These experiments confirmed that EGF induced down-regulation of both Cbl-b and the EGFR occurred only when the two proteins can bind to one another. ) . B, 293T cells were transfected the EGFR plasmid and Cbl-b N1/2 plasmid as indicated above the panels. Cells were starved (Ϫ) or stimulated (ϩ) with EGF for 6 h, and lysates were immunoblotted (IB) for Cbl-b, EGFR, and GFP, as indicated to the right of the panels. GFP was included in the 293T transfections as a control for protein loading and transfection efficiency. C, bacterially produced GST fusion proteins for the N-terminal half of Cbl-b (N1/2), the RING finger mutant of the N-terminal half of Cbl-b (C373A), or GST alone were incubated in the presence (ϩ) or absence (Ϫ) of recombinant wheat E2 (UbcH5B), recombinant wheat E1, 32 Plabeled ubiquitin, and ATP at 30°C for 90 min. The reaction mixture was separated by 7.5% SDS-polyacrylamide gel electrophoresis and visualized with a Storm PhosphorImager using Image Quant software (Molecular Dynamics). The position of the GST fusion proteins for the N-terminal region of the Cbl proteins is indicated by the arrow.
Down-regulation of the EGFR Signaling Complex by Cbl-b-
FIG. 6. Cbl-b down-regulation requires binding to the EGFR.
A, 293T cells were transiently transfected with Cbl-b and either wild type EGFR (EGFR) or mutant EGFR (Y1045F). Cells were starved (Ϫ) or stimulated (ϩ) with EGF as described in Fig. 2 , and lysates were immunoblotted for Cbl-b (HA), EGFR, or GFP as indicated to the right of the figure. GFP was included in the 293T transfections as a control for protein loading and transfection efficiency. B, the EGFR was immunoprecipitated (IP) from the lysates, and the immunoprecipitates were immunoblotted (IB) for Cbl-b or the EGFR. C, Cbl-b was immunoprecipitated from the lysates with anti-HA antibody, and the immunoprecipitates were immunoblotted for phosphotyrosine (p-Tyr) or Cbl-b (HA). The positions of the EGFR and Cbl-b are indicated by arrows to the left of the figure. the EGFR, EGF induced down-regulation of other components of the active signaling complex also were investigated in the MDA-MB-468 clones (Fig. 7) . Grb-2 and Shc were also downregulated upon EGF stimulation in clones that expressed either wild type Cbl-b (Fig. 7A, lanes 3 and 4) or Cbl-b N1/2 (Fig.  7A, lanes 7 and 8) but not in the Vector control cells (Fig. 7A,  lanes 1 and 2) . The time course of Grb-2 and Shc down-regulation was similar to that of the degradation of Cbl-b and the EGFR (Fig. 7B) . In addition, their down-regulation was blocked by lysosome inhibitors (e.g. NH 4 Cl; Fig. 7A, lanes 5, 6, 9 , and 10) or proteasome inhibitors (data not shown). In contrast, clones expressing the C373A RING finger mutant of Cbl-b did not down-regulate any components of the signaling complex (Fig. 7A, lanes 11 and 12) . Thus, the down-regulation of Grb-2 and Shc by Cbl-b were dependent upon the overexpression of Cbl-b containing both an intact TKB domain and RING finger. When Grb-2 and Shc were immunoprecipitated from EGFstimulated lysates in the presence of lactacystin, no evidence of ubiquitination or larger forms of the proteins could be demonstrated (data not shown). Interestingly, degradation of the p85 subunit of phosphatidylinositol 3-kinase was not observed upon EGF stimulation. We and others have shown that the p85 subunit is recruited to the activated EGFR upon stimulation through an interaction with the Cbl proteins (18, 50, 51) . Whether this lack of degradation indicates that not all proteins that become recruited to the active signaling complex are degraded or simply that the amount of p85 bound to the EGFR is only a small fraction of the total protein is unknown. ERK-2 was not down-regulated upon EGF stimulation, demonstrating that these results were not due to a general degradation of signaling molecules. DISCUSSION Cbl proteins have been shown to function as E3s for activated tyrosine kinases (20 -31) . Here we show that the Cbl-b protein is ubiquitinated and degraded upon EGF stimulation along with the EGFR (Figs. 1, 2, and 4) . We also found that c-Cbl is similarly degraded upon EGF stimulation (Fig. 2C) . c-Cbl protein ubiquitination has been described upon activation of the colony-stimulating factor-1 (CSF-1) receptor (28, 29, 52) . However, c-Cbl is not degraded along with the CSF-1 receptor. EGF-induced c-Cbl degradation has been noted recently, but no characterization of the structural requirements or its significance were reported (53) . Our results further demonstrate that EGF-induced degradation of Cbl-b requires an intact Cbl-b TKB domain, an intact Cbl-b RING finger, and binding of Cbl-b to the EGFR (Fig. 5 and 6 ). Previous work has demonstrated these same requirements for Cbl mediated degradation of the EGFR (23, (25) (26) (27) . The binding of the Cbl protein to the EGFR is required for activation of the E3 activity (26) . Whether the subsequent degradation of both the Cbl protein and the EGFR occurs while they are bound to one another or if they are degraded separately is unknown (see the discussion below). Other E3 proteins have been shown to ubiquitinate themselves and, thus, to target themselves for degradation. However, there is no evidence as yet that they are degraded along with their target proteins (37, 40 -42) . Our data showing degradation of an E3 in a coordinated fashion along with its target protein suggest an additional mechanism for the regulation of E3 activity.
The expression of both EGFR and a Cbl protein are required for down-regulation of either (Fig. 1, 2, and 5B). However, the relative amounts of the Cbl protein and the EGFR affect the ability to observe the down-regulation of the two proteins ( Fig.  2 and 5B). When Cbl proteins are in excess, EGF induces EGFR down-regulation with no apparent Cbl down-regulation. Conversely, when EGFR is in excess, EGF induces Cbl protein down-regulation with no apparent EGFR degradation. Finally, when the concentrations of both proteins are optimally titrated, activation-induced down-regulation of both proteins can be observed (e.g. Figs. 2C and 5B). Previous experiments were titrated to maximal EGFR degradation and, thus, used excess Cbl protein (18, 22, 23, 25, 27 ). The dosage effect described above could explain why we and others have not observed a decrease in Cbl proteins upon EGF stimulation. Together, these results suggest that the EGFR level determines the amount of degradation of Cbl-b (or c-Cbl) and that, in the presence of excess Cbl-b (or c-Cbl), the levels of EGFR are limiting (and vice versa). Limiting amounts of the E1 and/or E2 proteins could account for the results observed in the titration experiments, especially if E1, E2, and the E3 (Cbl-b) exist as a stable complex. However, this is unlikely. From the crystal structure of c-Cbl with the E2 UbcH7 and information on sites of E1-E2 binding, it appears that E2 must dissociate from the RING finger of Cbl to accept another ubiquitin molecule from E1 (54, 55) . Thus, the complex between Cbl-b and the E2 is likely to be transient, and Cbl is not likely to associate directly with E1. In addition, there is no evidence that the E1 and/or the E2 are degraded along with Cbl-b and the EGFR. Therefore each E1 and E2 molecule may participate in multiple rounds of ubiquitination. Our data also demonstrate that EGF-induced degradation of both the EGFR and the Cbl-b protein requires binding of the two proteins to one another (Fig. 6) . Therefore, the coordinated degradation of Cbl-b and the EGFR is most readily explained by a stoichiometric relationship between the two proteins that results from the interaction of the two proteins. We also show that EGF induces degradation of other components of the active signaling complex (e.g. Grb-2 and Shc) by a Cbl-b-dependent mechanism (Fig. 7) . The Cbl-b protein plays a key role in the EGF-induced degradation of these other proteins, since no degradation is seen in the absence of Cbl-b overexpression or when the inactive C373A RING finger mutant of Cbl-b is overexpressed. This suggests that the Cbl-b protein regulates the degradation of a signaling complex (including itself) and not simply the degradation of a single target protein. To our knowledge, this is the first description of E3-mediated degradation of multiple components of a receptor signaling complex. Grb-2 can interact directly with the C-terminal half of Cbl proteins and the cytoplasmic tail of the EGFR (10, 11, 56) . Shc can interact with both Grb-2 and the EGFR (56) . This raises the possibility that these proteins are degraded because of their association with either the EGFR or Cbl-b. However, both Grb-2 and Shc are degraded upon EGF stimulation in the cells overexpressing the Cbl-b N1/2 protein, which lacks the C-terminal half, suggesting that a direct interaction with the Cbl protein may not be necessary.
The mechanism of degradation of the EGFR signaling complex remains to be elucidated. The relationship between ubiquitination of plasma membrane proteins and their internalization, trafficking, and degradation is complex. In yeast, there are membrane proteins that are targeted for degradation in the vacuole by ubiquitination but whose degradation is independent of proteasome function (reviewed in Ref. 57) . Although many of these proteins are targeted for degradation by polyubiquitination, there are clear examples of proteins that are targeted for degradation by mono-, di-, and tri-ubiquitination (57) . In mammalian cells, ligand-induced internalization and degradation of the growth hormone receptor requires an intact ubiquitinating system, intact proteasome function, and intact lysosome function (58 -60) . However, ubiquitination of the growth hormone receptor itself is not required for degradation, but inhibition of proteasome function prevents internalization and degradation of the receptor (60) . Similar to the growth hormone receptor, the degradation of the EGFR is blocked by both proteasome and lysosome inhibitors (22, 46, 47) . Previous work suggests that the enhanced ubiquitination of the EGFR by Cbl proteins increases sorting of the internalized EGFR to the late endosome, where it is degraded by both proteasomal and lysosomal proteases (26) . Similarly, we have found that the EGF-induced, Cbl-b-dependent degradation of multiple components of the signaling complex is inhibited by both types of inhibitors ( Fig. 3 and 7 and data not shown). Again, this supports a common degradation pathway for the entire complex. It has been postulated that the cytoplasmic domains of the EGFR are degraded by the proteasomal proteases, and the extracellular domains are degraded by the lysosomal proteases (26) . Although it is clear that the degradation is dependent on both the proteasome and the lysosome, the mechanism by which the two are coupled remains unknown. It is possible that the entire EGFR-signaling complex traffics to the late endosome, where it is coordinately degraded by both lysosomal and proteasomal mechanisms. Alternatively, the components of the complex may be separately targeted to either the proteasome and/or lysosome. Although our experiments show that the Cbl-b protein coordinates the degradation of multiple components of the active EGFR signaling complex, we cannot exclude the possibility that other proteins or E3s are also required for this degradation to occur.
EGF induces ubiquitination of both the EGFR and Cbl-b (Fig. 4) . However, we have been unable to demonstrate EGFinduced ubiquitination of the Grb-2 or Shc proteins. It is possible that they do become ubiquitinated but that this is difficult to detect due to low steady state levels of the ubiquitinated species of these proteins. Alternatively, these non-ubiquitinated proteins may be targeted to lysosomal or proteasomal degradation as part of the EGFR-signaling complex because they are associated with other ubiquitinated proteins.
In conclusion, the results above demonstrate that the Cbl-b protein is degraded along with its substrate (the EGFR) in a ligand-dependent fashion and that Cbl-b regulates degradation of multiple proteins in the EGFR-signaling complex. Whether the observations we have made are specific to the interaction between Cbl proteins and the EGFR or are a general mechanism of Cbl protein action remains to be elucidated.
